Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel ...
CURE

Noninvasive Blood Test Launched for Myeloma MRD Monitoring

Quest Diagnostics debuts a new blood test for myeloma MRD, offering NGS-level sensitivity and a less invasive alternative to ...
GEN

Illumina Launches New MiSeq i100 Series with XLEAP Chemistry, RT Reagents

Weeks of teasers on social media noting that “Something big is coming. And it’s small,” have sparked a guessing game (and some patent searching) among NGS aficionados. But today, Illumina quelled the ...
ascopubs.org

Intra/intertumoral heterogeneity assessed by blood-based next generation sequencing (NGS) to predict inferior survival outcome compared to intratumoral heterogeneity assessed ...

Efficacy and safety of durvalumab plus tremelimumab versus standard chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis of phase III randomized controlled trials.